ZENTALIS PHARMACEUTICALS INC (ZNTL) Stock Price, Quote, News and Overview
NASDAQ:ZNTL - Nasdaq - US98943L1070 - Common Stock - Currency: USD
ZNTL Quote, Performance and Key Statistics
1.2
-0.04 (-3.23%)
The current stock price of ZNTL is 1.2 USD. In the past month the price decreased by -16.08%. In the past year, price decreased by -89.35%.
ZNTL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.84 | 323.71B | ||
| AMGN | AMGEN INC | 13.09 | 146.07B | ||
| GILD | GILEAD SCIENCES INC | 13.87 | 133.56B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.81B | ||
| ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
| ONC | BEIGENE LTD-ADR | 6.17 | 26.10B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
| NTRA | NATERA INC | N/A | 20.94B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
| BIIB | BIOGEN INC | 7.95 | 18.43B |
Related stock screener links
About ZNTL
Company Profile
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The company is headquartered in San Diego, California and currently employs 166 full-time employees. The company went IPO on 2020-04-03. The firm is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The firm is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.
Company Info
ZENTALIS PHARMACEUTICALS INC
10275 Science Center Drive, Suite 200
San Diego CALIFORNIA 10018 US
CEO: Anthony Y. Sun
Employees: 166
Phone: 18582634333
ZENTALIS PHARMACEUTICALS INC / ZNTL FAQ
What is the stock price of ZENTALIS PHARMACEUTICALS INC today?
The current stock price of ZNTL is 1.2 USD. The price decreased by -3.23% in the last trading session.
What is the ticker symbol for ZENTALIS PHARMACEUTICALS INC stock?
The exchange symbol of ZENTALIS PHARMACEUTICALS INC is ZNTL and it is listed on the Nasdaq exchange.
On which exchange is ZNTL stock listed?
ZNTL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ZENTALIS PHARMACEUTICALS INC stock?
16 analysts have analysed ZNTL and the average price target is 6.09 USD. This implies a price increase of 407.17% is expected in the next year compared to the current price of 1.2. Check the ZENTALIS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ZENTALIS PHARMACEUTICALS INC worth?
ZENTALIS PHARMACEUTICALS INC (ZNTL) has a market capitalization of 86.34M USD. This makes ZNTL a Micro Cap stock.
How many employees does ZENTALIS PHARMACEUTICALS INC have?
ZENTALIS PHARMACEUTICALS INC (ZNTL) currently has 166 employees.
What are the support and resistance levels for ZENTALIS PHARMACEUTICALS INC (ZNTL) stock?
ZENTALIS PHARMACEUTICALS INC (ZNTL) has a resistance level at 1.21. Check the full technical report for a detailed analysis of ZNTL support and resistance levels.
Is ZENTALIS PHARMACEUTICALS INC (ZNTL) expected to grow?
The Revenue of ZENTALIS PHARMACEUTICALS INC (ZNTL) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ZNTL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ZENTALIS PHARMACEUTICALS INC (ZNTL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ZNTL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ZNTL, evaluating the profitability, health, valuation and growth aspects
- ZENTALIS PHARMACEUTICALS INC (ZNTL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ZENTALIS PHARMACEUTICALS INC (ZNTL) Sales and EPS estimates to see what analysts future expectations are.
- ZENTALIS PHARMACEUTICALS INC (ZNTL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ZENTALIS PHARMACEUTICALS INC (ZNTL) Insider and Institutional Ownership to learn about the owners and their transactions.
- ZENTALIS PHARMACEUTICALS INC (ZNTL) Stock Chart to make your own analysis
- ZENTALIS PHARMACEUTICALS INC (ZNTL) Latest news and press-releases to stay up to date.
Does ZENTALIS PHARMACEUTICALS INC (ZNTL) stock pay dividends?
ZNTL does not pay a dividend.
When does ZENTALIS PHARMACEUTICALS INC (ZNTL) report earnings?
ZENTALIS PHARMACEUTICALS INC (ZNTL) will report earnings on 2025-08-07, before the market open.
What is the Price/Earnings (PE) ratio of ZENTALIS PHARMACEUTICALS INC (ZNTL)?
ZENTALIS PHARMACEUTICALS INC (ZNTL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.98).
What is the Short Interest ratio of ZENTALIS PHARMACEUTICALS INC (ZNTL) stock?
The outstanding short interest for ZENTALIS PHARMACEUTICALS INC (ZNTL) is 9.79% of its float. Check the ownership tab for more information on the ZNTL short interest.
ZNTL Technical Analysis
ZNTL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ZNTL. ZNTL has a great financial health rating, but its profitability evaluates not so good.
ZNTL Financial Highlights
Over the last trailing twelve months ZNTL reported a non-GAAP Earnings per Share(EPS) of -2.98. The EPS increased by 13.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -58.38% | ||
| ROE | -75.9% | ||
| Debt/Equity | 0 |
ZNTL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to ZNTL. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of -3.79% and a revenue growth -100% for ZNTL